encyclopedia jump navigation jump search non-alcoholic_fatty_liver_disease name non-alcoholic_fatty_liver_disease non-alcoholic_fatty_liver_disease micrograph non-alcoholic_fatty_liver_disease liver 
stain symptom liver dysfunction complication liver_cancer liver failure disease duration term type liver steatohepatitis cause risk factor syndrome diabete type liver disease method liver biopsy treatment weight loss diet exercise prognosis type frequency population death risk death year 
non-alcoholic_fatty_liver_disease non-alcoholic_fatty_liver_disease build-up liver cause alcohol use type liver steatohepatitis liver liver damage nash liver liver inflammation complication cirrhosis liver_cancer liver failure disease 
risk factor diabete obesity diet fructose age non-alcoholic_fatty_liver_disease liver disease type liver disease non-alcoholic_fatty_liver_disease insulin resistance syndrome 
liver biopsy 
treatment weight loss change exercise evidence pioglitazone vitamin  nash risk year 
non-alcoholic_fatty_liver_disease liver disorder country american  people population non-alcoholic_fatty_liver_disease cause liver disease  people united states non-alcoholic_fatty_liver_disease burden us103 content 
sign symptom risk factor genetics diet diagnosis definition monitor management lifestyle surgery outcome epidemiology history children research diagnosis drug development reference link 
sign symptom 
non-alcoholic_fatty_liver_disease evidence steatosis absence factor accumulation liver alcohol drinksweek men women heredity deficiency nutrition choline alcohol use  men  women hepatitis condition cause liver non-alcoholic_fatty_liver_disease 
non-alcoholic_fatty_liver_disease category form 
presence steatosis nafl evidence injury form hepatocyte balloon presence inflammation hepatocyte injury fibrosis 
people non-alcoholic_fatty_liver_disease 
laboratory profile 
non-alcoholic_fatty_liver_disease symptom liver dysfunction 
non-alcoholic_fatty_liver_disease liver biopsy liver function test routine blood test steatosis biopsy 
case symptom sign liver disease test liver non-alcoholic_fatty_liver_disease 
symptom sign liver disease test liver steatosis risk factor obesity diabete mellitus cause alcohol 
patient fatigue malaise discomfort 
jaundice risk factor 
non-alcoholic_fatty_liver_disease insulin resistance syndrome obesity diabete mellitus type blood pressure insulin resistance age bmy hypoxia sleep predictor disease progression 
non-obese people non-alcoholic_fatty_liver_disease non-alcoholic_fatty_liver_disease insulin sensitivity risk liver level consequence capacity fat function tissue de novo 
non-alcoholic_fatty_liver_disease men women deficiency genetics 
risk factor non-alcoholic_fatty_liver_disease 
family history diabete type report family member non-alcoholic_fatty_liver_disease 
risk fibrosis family member person prevalence non-alcoholic_fatty_liver_disease individual susceptibility individual 
mutation non-alcoholic_fatty_liver_disease susceptibility cohort non-synonymous polymorphism pnpla3 tm6sf2 non-alcoholic_fatty_liver_disease presence severity role patient diagnosis 
non-alcoholic_fatty_liver_disease component aasld screen family member confirmation heritability evidence aggregation twin study 
link dysbiosis gut liver disease non-alcoholic_fatty_liver_disease 
patient nash level blood ethanol 
patient non-alcoholic_fatty_liver_disease choline depletion choline metabolism diet 
diet composition quantity acid lipid fructose sugar role disease progression nafl nash fibrosis deficiency development non-alcoholic_fatty_liver_disease interplay environment diet genetics gut development progression non-alcoholic_fatty_liver_disease pathophysiology 
non-alcoholic_fatty_liver_disease lobular portal inflammation balloon steatosis balloon inflammation 
feature diagnosis portal inflammation body body nucley steatosis fibrosis death apoptosis steatosis inflammation hallmark 
mechanism second hit injury change steatosis inflammation 
stress imbalance abnormality cause second hit phenomenon model hit second hit model disease factor gene nutrition impact lifestyle change genetics evolution non-alcoholic_fatty_liver_disease pathology non-alcoholic_fatty_liver_disease disease impact organ pathway liver 
liver disease share feature pathway 
patient level blood ethanol proteobacteria alcohol mechanism elevation inflammation addiction ethanol pathway glucose researcher liver disease disease intake tissue inflammation perturbation homeostasis lifestyle change addition weight risk factor change gut diagnosis 
liver biopsy tissue examination test gold standard non-alcoholic_fatty_liver_disease nafl nash form liver disease severity inflammation fibrosis 
people non-alcoholic_fatty_liver_disease liver biopsy risk routine diagnosis method liver ultrasonography liver mry 
people liver ultrasonography biopsy evidence routine liver function blood test non-alcoholic_fatty_liver_disease biopsy procedure 
find liver enzyme liver ultrasound scan mry 
ultrasound problem 
guideline enzyme level rule non-alcoholic_fatty_liver_disease range disease easl screen steatosis non-alcoholic_fatty_liver_disease predictor disease evolution diabete type event hypertension 
blood test diagnosis rule erythrocyte sedimentation rate glucose albumin kidney function 
liver protein blood clote study ratio 
people liver injury blood test rule hepatitis hepatitis virus cytomegalovirus rubella autoimmune disease 
activity patient hormone 
blood test 
guideline liver biopsy patient non-alcoholic_fatty_liver_disease risk fibrosis liver disease liver disease 
presence syndrome non-alcoholic_fatty_liver_disease fibrosis score liver stiffness vcte patient risk steatohepatitis fibrosis 
non-alcoholic_fatty_liver_disease patient screen carcinoma liver_cancer gastroesophageal varice 
pathology report nafl inflammation steatosis lobular portal inflammation balloon presence absence fibrosis comment severity 
easl activity lifestyle development progression non-alcoholic_fatty_liver_disease 
algorithm balloon use non-alcoholic_fatty_liver_disease activity score nas severity nash diagnosis 
activity fibrosis saf score score system aasld use nas saf score system 
system screen easl non-alcoholic_fatty_liver_disease outcome result complication atherosclerosis cause majority non-alcoholic_fatty_liver_disease death patient non-alcoholic_fatty_liver_disease risk morbidity mortality modification disease risk factor patient non-alcoholic_fatty_liver_disease 
aasld patient nash varice liver_cancer 
routine screen liver_cancer liver biopsy patient basis definition 
non-alcoholic_fatty_liver_disease non-alcoholic_fatty_liver_disease accumulation fat liver cause alcohol use 
non-alcoholic_fatty_liver_disease continuum liver abnormality liver steatohepatitis 
disease accumulation liver steatosis 
liver liver function mechanism insult liver steatohepatitis state inflammation fibrosis monitor 
screen non-alcoholic_fatty_liver_disease liver fibrosis year adult year children liver fibrosis elf blood test follow-up people obesity insulin resistance homeostasis model assessment insulin resistance 
people nash fibrosis hypertension monitor risk disease progression management 
guideline association study liver disease institute health care excellence association study liver lifestyle 
weight loss treatment non-alcoholic_fatty_liver_disease 
offer people non-alcoholic_fatty_liver_disease weight loss programme weight loss advice improvement non-alcoholic_fatty_liver_disease blood test ultrasound image liver biopsy 
combination diet exercise non-alcoholic_fatty_liver_disease insulin resistance support therapy people non-alcoholic_fatty_liver_disease condition disease motivation change diet 
treatment non-alcoholic_fatty_liver_disease nutrition people non-alcoholic_fatty_liver_disease diet diet diet result scheme reduction inflammation fibrosis weight loss evidence intervention individual liver 
easl energy restriction 500-1000 diet target weight loss obeseoverweight non-alcoholic_fatty_liver_disease low fat carbohydrate diet carbohydrate protein diet diet beverage food fructose 
guideline recommendation vitamin people non-alcoholic_fatty_liver_disease acid supplementation trial review acid supplementation non-alcoholic_fatty_liver_disease nash dose gram dose duration month treatment improvement liver fat guideline acid treatment non-alcoholic_fatty_liver_disease nash patient non-alcoholic_fatty_liver_disease 
alcohol factor people non-alcoholic_fatty_liver_disease easl alcohol consumption 30gday men 20gday women 
easl limitation consumption coffee 
compound curcumin tea enhancement non-alcoholic_fatty_liver_disease grade reduction look therapy activity 
weight loss process people 
activity diet people non-alcoholic_fatty_liver_disease people activity weight loss adaptation intake activity liver fat body weight reduction weight loss exercise diet way liver fat help fibrosis remission exercise steatosis aspect liver approach exercise diet exercise resistance train result train train intensity exercise chance nash steatohepatitis fibrosis easl minweek session intensity activity resistance train 
liver fat choice activity individual preference goal engagement activity increase level inactivity 
liver disease nash fibrosis 
medicine non-alcoholic_fatty_liver_disease approval drug liver fat loss 
treatment marker transaminase level abnormality endpoint 
insulin sensitizers insulin resistance non-alcoholic_fatty_liver_disease trial feature lead resolution steatohepatitis fibrosis 
side-effect drug fracture risk fluid retention heart_failure bladder cancer weight gain adoption side-effect use patient nash 
use metformin study improvement liver condition improvement insulin resistance serum improvement guideline pioglitazone care adult liver fibrosis diabete 
vitamin treatment patient nash 
improvement liver biochemistry histology people non-alcoholic_fatty_liver_disease treatment 
non-alcoholic_fatty_liver_disease patient risk disease treatment 
people non-alcoholic_fatty_liver_disease risk liver injury statin aasld easl 
patient cirrhosis case cirrhosis use patient non-alcoholic_fatty_liver_disease 
guideline liver enzyme level month start treatment pentoxifylline improvement appearance liver tissue microscope trial 
acid  aasld trial 
effect inflammation dysbiosis patient non-alcoholic_fatty_liver_disease surgery 
surgery method individual non-alcoholic_fatty_liver_disease weight loss inflammation fibrosis aasld surgery nash basis bariatric surgery program 
patient liver disease liver failure liver_cancer liver transplantation procedure easl 
survival transplantation disease people nash liver transplantation disease symptom 
people non-alcoholic_fatty_liver_disease improvement steatosis resolution surgery 
non-alcoholic_fatty_liver_disease cause liver transplantation outcome 
cause disease mechanism disease stage find insight mechanism 
non-alcoholic_fatty_liver_disease disease organ pathway liver 
progression rate fibrosis human nash year year non-alcoholic_fatty_liver_disease rate stage manifestation individual fibrosis human nash human non-alcoholic_fatty_liver_disease study non-alcoholic_fatty_liver_disease patient 
year survival rate 
non-alcoholic_fatty_liver_disease risk factor fibrosis hypertension kidney_disease fibrillation infarction stroke death cause quality evidence study 
risk liver_cancer 
liver_cancer non-alcoholic_fatty_liver_disease cause liver transplantation 
liver_cancer nash absence cirrhosis case people cirrhosis risk liver_cancer 
rate liver_cancer cause liver_cancer 
non-alcoholic_fatty_liver_disease risk factor liver_cancer cirrhosis patient year period 
non-alcoholic_fatty_liver_disease precursor syndrome influence 
presence stage fibrosis factor event mortality non-alcoholic_fatty_liver_disease 
non-alcoholic_fatty_liver_disease cirrhosis liver failure liver_cancer majority death non-alcoholic_fatty_liver_disease patient failure meta-analysis patient non-alcoholic_fatty_liver_disease year risk event epidemiology 
percentage people non-alcoholic_fatty_liver_disease range part world study liver enzyme prevalence ultrasonography proton nmr spectroscopy study population non-alcoholic_fatty_liver_disease united states population liver prevalence europe country data children age prevalence population study data child obesity clinics   usa 
non-alcoholic_fatty_liver_disease hispanics rate obesity type diabete population white black liver disease children teenager adult 
non-alcoholic_fatty_liver_disease men women 
disease obesity proportion sufferer weight 
lean non-alcoholic_fatty_liver_disease american european country incidence india proportion non-alcoholic_fatty_liver_disease non-alcoholic_fatty_liver_disease 
lean non-alcoholic_fatty_liver_disease people risk median survival rate liver transplantation non-alcoholic_fatty_liver_disease people cohort study 
progression non-alcoholic_fatty_liver_disease people 
people suffer non-alcoholic_fatty_liver_disease population treatment obesity 
study children ultrasound age non-alcoholic_fatty_liver_disease year elastography deposit liver non-alcoholic_fatty_liver_disease half 
scan liver scare cirrhosis history 
case liver samuel zelman liver hospital employee bottle coca-cola day 
trial year half people find liver liver diabete atherosclerosis choline depletion sugar occurrence diabete 
name steatohepatitis jurgen ludwig colleague mayo clinic order awareness existence pathology report patient paper time landmark paper start condition series meet topic start non-alcoholic_fatty_liver_disease term criteria pathology committee nih research network nas score system children 
liver disease non-alcoholic_fatty_liver_disease liver disease children adolescent non-alcoholic_fatty_liver_disease syndrome cluster risk factor development disease type diabete mellitus 
study obesity insulin-resistance contributor development non-alcoholic_fatty_liver_disease liver disease hepatitis disease atherosclerosis risk non-alcoholic_fatty_liver_disease children year age diagnosis year age year children symptom non-alcoholic_fatty_liver_disease 
boy non-alcoholic_fatty_liver_disease girl weight gain childhood adolescence risk non-alcoholic_fatty_liver_disease life adult non-alcoholic_fatty_liver_disease follow-up study risk factor childhood bmy plasma insulin level sex background variant birth weight risk factor adulthood non-alcoholic_fatty_liver_disease study steatosis children suspicion non-alcoholic_fatty_liver_disease children steatosis prognosis adult non-alcoholic_fatty_liver_disease adult 
children non-alcoholic_fatty_liver_disease nash children obesity adult fibrosis course children adult 
diagnosis non-alcoholic_fatty_liver_disease children development liver disease adulthood children non-alcoholic_fatty_liver_disease 42-59 pain symptom quadrant pain acanthosis patient hepatomegaly  children non-alcoholic_fatty_liver_disease 
liver biopsy diagnosis children diagnosis therapy easl fibrosis test radiation force impulse image serum order number biopsy children non-alcoholic_fatty_liver_disease screen liver fibrosis year liver fibrosis elf blood test study resonance alternative ultrasonography 
lifestyle modification activity change line treatment aasld easl liver histology aminotransferase level 
term treatment vitamin  liver health children use vitamin  children liver fibrosis diabete treatment childhood non-alcoholic_fatty_liver_disease weight loss 
evidence undernutrition susceptibility childhood progression lifespan research diagnosis biomarker 
diagnosis liver biopsy epidemiology method non-alcoholic_fatty_liver_disease disease progression research priority search biomarker non-alcoholic_fatty_liver_disease image blood test score system 
resonance sensitivity fat accuracy fibrosis non-alcoholic_fatty_liver_disease bmy inflammation alternative non-alcoholic_fatty_liver_disease progression ultrasonography blood test 
nature review proton density fat fraction estimation resonance image gold standard test steatosis 
elastography fibrosis cirrhosis routine set objectivity ultrasonography accuracy resonance plasma fragment level biomarker drug development 
drug development nash 
drug target site lipid glucose homeostasis stress target hepatocyte signal hepatocyte target cell activation fibrogenesis trial elafibranor acid selonsertib phase phase non-alcoholic_fatty_liver_disease disease organ tissue combination therapy compound conjugate therapy drug therapy therapy lifestyle change way increase drug efficiency trial month use administration lobby 
france syndicate beverage de france drink producer coca-cola france pepsico france journal enchain consumer communication website pathology pathology soda illness language abuse shortcut consumption beverage 
page website disinformation 
liver poultry pathophysiology non-alcoholic_fatty_liver_disease human 
